Company profile
Harrow, Inc.
HROW · NASDAQ (Harrow's July 2026 release identifies Harrow as Nasdaq-listed under HROW and confirms exclusive US commercialization rights to Byooviz and Opuviz. Sources: https://investors.harrow.com/news-releases/news-release-details/harrow-announces-commercial-launch-byoovizr-united-states/ ; https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/form10-k.htm Entity resolved by asset-pipeline-v2.)
Share price · HROW
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Aflibercept(Eylea) | Approved | VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic | Age-Related Macular Degeneration |
Ranibizumab(Lucentis) | Approved | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration |
| Preclinical | Voltage-gated sodium channels (Nav) on sensory nerve membranesSmall molecule | Age-Related Macular Degeneration |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.